Arcticzymes Technologies ASA
OSE:AZT

Watchlist Manager
Arcticzymes Technologies ASA Logo
Arcticzymes Technologies ASA
OSE:AZT
Watchlist
Price: 16.45 NOK -2.08% Market Closed
Market Cap: 840.1m NOK
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one AZT stock under the Base Case scenario is 23.83 NOK. Compared to the current market price of 16.45 NOK, Arcticzymes Technologies ASA is Undervalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AZT Relative Value
Base Case
23.83 NOK
Undervaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8.1
P/S
P/S
Price to Sales
8.1
vs History
90
vs Industry
47
Median 3Y
14.5
Median 5Y
21.9
Industry
7
Forward
7.2
More Details
111
P/E
P/E
Price to Earnings
111
vs History
19
vs Industry
1
Median 3Y
88.7
Median 5Y
79.9
Industry
21.8
Forward
93.1
More Details
477.6
P/OCF
P/OCF
Price to OCF
477.6
vs History
3
vs Industry
0
Median 3Y
62.1
Median 5Y
63.3
Industry
19.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
0
Median 3Y
73.7
Median 5Y
73.7
Industry
22.7
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
93
vs Industry
33
Median 3Y
6.3
Median 5Y
12.5
Industry
2.4
More Details
6.5
EV/S
EV/S
Enterprise Value to Sales
6.5
vs History
93
vs Industry
43
Median 3Y
13
Median 5Y
21.2
Industry
7.3
Forward
5.8
More Details
6.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.8
vs History
91
vs Industry
48
Median 3Y
13.7
Median 5Y
19.3
Industry
8.8
More Details
128.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
128.2
vs History
6
vs Industry
1
Median 3Y
70
Median 5Y
68.8
Industry
4
Forward
63.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
1
Median 3Y
69.2
Median 5Y
69.2
Industry
3.7
Forward
190.5
More Details
382.9
EV/OCF
EV/OCF
Enterprise Value to OCF
382.9
vs History
3
vs Industry
0
Median 3Y
55.6
Median 5Y
60.3
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
1
Median 3Y
65.3
Median 5Y
67.2
Industry
3.2
More Details
4
EV/IC
EV/IC
Enterprise Value to IC
4
vs History
93
vs Industry
32
Median 3Y
17.6
Median 5Y
31.5
Industry
4.5
More Details

Multiples Across Competitors

AZT Competitors Multiples
Arcticzymes Technologies ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Arcticzymes Technologies ASA
OSE:AZT
840.1m NOK 8.1 111 128.2 -506.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 127 228.5 -166 954.5 -202 736 -200 422.5
US
Abbvie Inc
NYSE:ABBV
341.3B USD 6.1 80.5 15.9 24
US
Amgen Inc
NASDAQ:AMGN
152.4B USD 4.6 37.3 15.3 27.1
US
Gilead Sciences Inc
NASDAQ:GILD
128.6B USD 4.5 268 10.6 13.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.2B USD 11.6 -239.3 26.2 27.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 005.5 -511.8 -557.3 -542.4
AU
CSL Ltd
ASX:CSL
121.6B AUD 5.1 28.3 17.4 21.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
64.2B USD 4.5 14.6 9 10.1
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.8 -57.6
NL
argenx SE
XBRU:ARGX
34.6B EUR 17.9 47 -2 655.6 -1 780.5
P/S Multiple
Revenue Growth P/S to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average P/S: 3 193 574.1
8.1
17%
0.5
FR
Pharnext SCA
OTC:PNEXF
35 127 228.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.6
10%
1.2
US
E
Epizyme Inc
F:EPE
2 005.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5.1
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.5
6%
0.8
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
NL
argenx SE
XBRU:ARGX
17.9
39%
0.5
P/E Multiple
Earnings Growth PEG
NO
Arcticzymes Technologies ASA
OSE:AZT
Average P/E: 83.8
111
61%
1.8
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -166 954.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
37.3
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
268
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -239.3 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.8 N/A N/A
AU
CSL Ltd
ASX:CSL
28.3
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.6
11%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
NL
argenx SE
XBRU:ARGX
47
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBITDA: 31.8
128.2
96%
1.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 736 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.9
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
15.3
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.6
7%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.2
18%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.3 N/A N/A
AU
CSL Ltd
ASX:CSL
17.4
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 655.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
Arcticzymes Technologies ASA
OSE:AZT
Average EV/EBIT: 20.6
Negative Multiple: -506.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 422.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
27.1
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.3
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.4
15%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -542.4 N/A N/A
AU
CSL Ltd
ASX:CSL
21.8
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.1
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 780.5 N/A N/A

See Also

Summary
AZT intrinsic value, competitors valuation, and company profile.
DCF Valuation
AZT stock valuation using Discount Cash Flow valuation method.
Relative Valuation
AZT stock valuation using valuation multiples.
Wall Street Estimates
AZT price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
AZT stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 251,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.